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Objectives: Evaluate risk factors and clinical outcomes of infections caused by Enterobac-
teriaceae resistant to third-generation cephalosporins present in samples collected upon
hospital admission.
Methods: Risk factors were evaluated using a 1:2 ratio case–control study. Inﬂuence of resis-
tance on the appropriateness of antibiotic therapy, length of stay, and hospital mortality
were prospectively evaluated. Characteristics independently associated with the presence
of  resistant enterobacteria were assessed by logistic regression.
Results: Enterobacteria resistant to third-generation cephalosporins were quite common
(26.0%). Male gender (OR: 2.66; 95% CI, 1.17–5.06; p = 0.019), invasive prosthesis (OR: 3.79;
95%  CI, 1.29–11.08; p = 0.015), previous use of cephalosporins (OR: 2.77; 95% CI, 1.10–6.97;
p  = 0.029) and hospitalization in the last 6 months (OR: 5.33; 95% CI, 2.29–12.44; p < 0.001)
were independently associated with the presence of these microorganisms. These bacte-
ria  were associated with higher frequency of inappropriate antimicrobial therapy, worse
clinical response, and longer length of stay. Finally, older age, admission to the ICU, and
site of infection other than urinary tract were independently associated to higher hospital
mortality.
Conclusions: Risk factors identiﬁed in this study may help in the choice of empirical antibiotictherapy for infected patients suspected of harboring these bacteria and in the early imple-mentation of measures to
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Introduction
Enterobacteriaceae are responsible for a wide variety of
nosocomial and community-acquired infections.1,2 Given
their versatility, low toxicity, and broad spectrum of
action, -lactam antibiotics, such as the third generation
cephalosporins, are the main choice for the treatment of
infections caused by these microorganisms.3 However, along
with their overuse, a decrease in the effectiveness of these
compounds has been observed in recent years.4 In Entero-
bacteriaceae, antibiotic resistance due to the production of
extended-spectrum -lactamase (ESBL-E) and overexpression
of AmpC cephalosporinase (AmpC-E) is cause for great con-
cern and produce a signiﬁcant impact both on empirical and
deﬁnitive therapy.5,6 Moroeover, this resistance may lead to
delays in the onset of effective antimicrobial therapy, with
consequent impact on clinical results, and higher mortality
rate.7
Many  studies have attempted to determine the risk factors
for nosocomial infections caused by Enterobacteriaceae resis-
tant to third-generation cephalosporins, and more  recently,
some publications have addressed those cases identiﬁed at the
time of hospital admission.7–9 Our aim was to determine the
frequency, risk factors, and the impact on clinical outcome of
the presence of Enterobacteriaceae resistant to third-generation
cephalosporins isolated in samples collected within the ﬁrst
48 h of hospitalization of patients admitted to a university
hospital.
Material  and  methods
Study  setting  and  subjects
This two-phase study was conducted from August 2011 to July
2012, in a 501-bed University Hospital of Minas Gerais, Brazil.
Firstly, a 1:2 ratio case–control protocol was run, in order to
identify characteristics associated with colonization or infec-
tion by resistant Enterobacteriaceae in samples obtained during
the ﬁrst 48 h of hospitalization. Thereafter, in the second
phase of the study, the included patients were followed up in
order to identify the impact of these microorganisms in some
clinical endpoints. Patients at least 18 years old, whose culture
requested by the attending physician grew enterobacteria in
samples collected in pre-speciﬁed days after hospitalization
were assessed for potential inclusion. Patients with enterobac-
teria resistant to carbapenems were excluded from the study.
All included patients lived in the metropolitan area of Belo
Horizonte, Minas Gerais state.
Eligible patients were screened in the emergency service of
our hospital and categorized into one of two groups: (i) cases,
referring to those colonized or infected by Enterobacteriaceae
resistant to third-generation cephalosporins and, (ii) controls,
patients colonized or infected by Enterobacteriaceae susceptible
to third-generation cephalosporins. For each case included in
the study, two  controls were selected sequentially on the same
day. Each patient was included in the study only once.
Patients were further categorized as (i) infected patients,
if there was a clinical suspicion of active infection 1 5;1  9(3):239–245
leading to prescription of antibiotic therapy, and (ii) col-
onized patients, if there was no clinical suspicion of infection
or if the enterobacteria were isolated from surveillance sam-
ples. Surveillance samples were samples collected at the time
of hospital admission via swabs, as a routine procedure in
patients transferred from other hospitals aiming at detecting
the presence of patients colonized with multidrug-resistant
bacteria.
Study  procedures  and  deﬁnitions
Demographic, clinical, and epidemiological data were col-
lected using a dedicated case report form. Data was obtained
from interviews and by consulting electronic and printed
records. The following variables were collected: age, sex,
microbiological data, site of infection, presence of comor-
bidities (diabetes, chronic renal failure, liver failure, solid
tumor, malignant hematological disease, heart failure, and
others), known immunosuppression (HIV infection, neutrope-
nia with PMN  <500 cells/mm3, use of corticosteroids in doses
above 15 mg/day of prednisone or equivalent, use of other
immunosuppressive drugs), hospitalization and previous use
of antibiotics, performance of invasive procedures in the last
four weeks, use of invasive prosthesis, presence of stoma,
recurrent urinary tract infection (UTI), adequacy of initial
empiric antibiotic treatment (only for infected patients), hos-
pitalization at the intensive care unit (ICU), response to the
antibiotic therapy, all-cause hospital mortality, and hospital
length of stay.
Recurrence of urinary tract infection (UTI) was deﬁned as
the development of two or more  documented episodes in the
last six months. For the subgroup of infected patients, empiri-
cal treatment was considered adequate when an antimicrobial
regimen included an active antibiotic against the isolated
enterobacteria, and was initiated at the recommended dose in
the ﬁrst 24 h after sample collection. Inadequate antimicrobial
treatment included absence of antimicrobial agents indicated
for a speciﬁc class of microorganisms and administration of
an antimicrobial agent to which the isolated microorganism
was resistant.10
In this subset of patients, clinical response to the antimi-
crobial treatment was classiﬁed as: “complete or partial
resolution”, referring to the patients who presented total or par-
tial improvement of fever, leukocytosis and clinical signs of
infection, and “therapeutic failure or uncertain result”,  for those
who, respectively, showed no decrease in these parameters at
all or persisted with symptoms and signs that were not clearly
attributable to infection.11
For the infected patients clinical outcomes were ICU admit-
tance during follow-up, all-cause hospital mortality, and
length of hospital stay.
Microbiological  analysisBacterial identiﬁcation and antimicrobial susceptibility test-
ing, including production of -lactamases, were carried out
in accordance with the recommendations of the Clinical and
Laboratory Standards Institute (CLSI).12 Identiﬁcation and ESBL
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270 Enterobacteriaceae were isolated in
260 adult patients in the first 48 hours of
hospitalization 
238 patients were eligible for the
inclusion
62 patients with
Enterobacteriaceae
resistant to third-generation
cephalosporins - CASES
22 samples with
Enterobacteriaceae
producing AmpC β-
lactamases.
40 samples with
Enterobacteriaceae
ESBL-producing
organisms
176 patients with
Enterobacteriaceae sensitive to
third-generation
cephalosporins.
124 patients-
CONTROLS
52 were not
selected
22 patients were excluded
-16 had more than one
hospital admission during
the study
-6 had carbapenem-
resistant
Enterobacteriaceae
Fig. 1 – Flowchart presenting the procedures for inclusion in the study.
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droduction were conﬁrmed by using the API 20E® and Vitek
I® systems (both from bioMérieux).
tatistical  analysis
ategorical variables were compared by using the Pearson’s
hi-square test (or Fischer’s exact test, as indicated), and pre-
ented with the corresponding 95% conﬁdence intervals (CI).
ontinuous variables were compared using Student’s t-test.
n cases of non-normal distribution of quantitative variables,
on-parametric tests were used, such as Mann–Whitney U
est.
Non-conditional multivariate logistic regression analysis
as conducted to determine the independent risk factors
ssociated with the presence of resistant enterobacteria. All
ariables presenting the p-value <0.20 in univariate analysis
ere included in the multivariate model. Furthermore, the
ndependent risks factors associated with in-hospital death
ere investigated in a multivariate analysis excluding the
olonized patients. Using the same criteria described above (p-
alue <0.20 in the univariate analysis), the following variables
ere include in this analysis: age, presence of two or more
omorbidities, presence of UTI, admittance to ICU, inappro-
riate empirical antibiotic therapy, and presence of resistant
nterobacteria (cases). For the multivariate models, backward
ethod was used, and the Hosmer and Lemeshow test was
pplied to assess the models’ adequacy.
Finally, to evaluate the impact of the infections caused
y enterobacteria resistant to third-generation cephalosporins
n hospital length of stay, a Cox proportional hazards analysis
as conducted. The variable “age” was included as a binary
ariable (greater than or less than 50 years). Discharges by
eath were censored. For all analyses, a two-tailed value ofp < 0.05 was considered signiﬁcant. Statistical analyses were
performed by using SPSS version 16.0 software.
Results
Selection  of  studied  patients
During the study period, 238 adult patients had one or
more Enterobacteriaceae isolated from samples collected in the
ﬁrst 48 h after hospital admission. Of this total, 62 (26.0%)
patients had Enterobacteriaceae resistant to third-generation
cephalosporins. The ﬂowchart presenting the inclusion pro-
cedures is summarized in Fig. 1.
Demographic  characteristics  and  comorbidities
Results of univariate analysis are shown in Table 1. Case
patients had higher mean age (56.7 ± 19.1 vs. 46.9 ± 19.6,
p = 0.001), were more  frequently male (53.2% vs. 25.8%;
p < 0.001), and usually presented two or more  comorbidities
(50.0%vs. 34.7%, p = 0.044). Speciﬁcally, heart failure (HF) was
the only comorbidity signiﬁcantly more  frequent among cases
(17.7% vs. 7.3%, p = 0.031).
Microbiological  results
Taking into account the whole sample of patients, there was a
predominance of infected patients (81.7%); however, there was
signiﬁcantly more  colonized individuals among cases as com-
pared to controls (25.8% vs. 12.9%, P = 0.028). Out of all cases,
14.5% were detected through surveillance cultures. For both
groups, UTI was the most common site of infection (83.1% in
the control group vs. 59.7% in cases, p < 0.001). A signiﬁcant
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Table 1 – Demographic and clinical characteristics of patients in whom there was isolation of Enterobacteriaceae in
samples collected in the ﬁrst 48 h of hospitalization.
Variables Casesn = 62 Controlsn  = 124 p-value OR (95% CI)
Male, n (%) 33 (53.2) 32 (25.8) <0.001 3.27 (1.72–6.21)
Age, years, mean (SD) 56.7 (19.1) 46.9 (19.6) 0.001
Comorbidities
Diabetes mellitus, n (%) 14 (22.4) 24 (19.4) 0.607 1.22 (0.58–2.56)
Chronic renal failure, n (%) 3 (4.8) 4 (3.2) 0.586 1.53 (0.33–7.04)
Liver failure, n (%) 3 (4.8) 3 (2.4) 0.379 2.05 (0.40–10.47)
Solid Tumor, n (%) 22  (35.5) 36 (29.0) 0.371 1.34  (0.70–2.57)
Malignant hematological disease, n (%) 3  (4.8) 4 (3.2) 0.586 1.53  (0.33–7.04)
Heart Failure, n (%) 11  (17.7) 9 (7.3) 0.031 2.73 (1.07–6.99)
Presence of 2 or more comorbidities 31 (50.0) 43 (34.7) 0.044 1.88 (1.01–3.50)
Coexisting conditions
Transplant 4  (6.5) 10 (8.1) 0.694 0.79 (0.24–2.61)
Immunosuppression, n (%) 19 (30.6) 30 (24.2) 0.346 1.38 (0.70–2.73)
Immunosuppressive drugs, n (%) 16 (25.8) 26 (21.0) 0.457 1.31 (0.64–2.68)
HIV, n (%) 2 (3.2) 2 (1.6) 0.475 2.03 (0.28–14.79)
Primary site of infection <0.001
Urinary tract, n (%) 37 (59.7) 103 (83.1)
Respiratory tract, n (%) 2 (3.2) 4 (3.2)
Bloodstream, n (%) 2 (3.2) 6 (4.8)
Skin and soft tissue, n (%) 6 (9.7) 6 (4.8)
Other sites, n (%) 6 (9.7) 5 (4.0)
Severity on admission (Manchester)
Orange or red risk rating, n(%) 21 (33.9) 
difference was observed in the frequency of species of Entero-
bacteriaceae between the groups (p < 0.001). Escherichia coli was
the most frequently species isolated from the controls (79.0%)
whereas in the cases prevailed Klebsiella pneumoniae (30.6%)
with E. coli (30.6%). Enterobacter sp. and Serratia marcescens were
isolated only from cases (24.2% and 6.0%, respectively).
Risk  factors  for  Enterobacteriaceae  resistant  to
third-generation  cephalosporins
The univariate analysis testing the variables associated with
the presence of Enterobacteriaceae resistant to third-generation
cephalosporins is summarized in Table 2. The composite pres-
ence of invasive prosthesis or tunneled catheters and presence
of stoma were signiﬁcantly more  frequent among cases
than controls. The main types of stoma observed in these
patients were cystostomy (41.2%), colostomy (23.5%), and tra-
cheostomy (17.6%). Finally, previous contact with health care
services (performance of invasive procedures and/or prior
hospitalization) and previous use of antibiotics were also more
frequent in patients with resistant Enterobacteriaceae.
Previous use of cephalosporins in last 90 days, presence of
invasive prosthesis or tunneled catheters, hospitalization in
last six months, and male gender were independently associ-
ated with the presence of Enterobacteriaceae resistant to third
generation cephalosporins as shown in Table 3.
Impacts  on  clinical  outcomeWe  prospectively tested the impact of the presence of enter-
obacteria resistant to third-generation cephalosporins on
some clinical endpoints (Table 4). Inappropriate empirical38 (30.6) 0.656 1.16 (0.61–2.22)
antibiotic therapy was signiﬁcantly higher among cases (73.3%
vs. 10.3%, p < 0.001). Moreover, patients with resistant Entero-
bacteriaceae were more  often admitted to the ICU (p = 0.003),
had worse clinical response to the antimicrobial therapy
(p = 0.029), and had higher length of stay (p < 0.001). Although
the death rate was higher among cases (21% vs. 10.5%), this dif-
ference did not quite reach statistical signiﬁcance (p = 0.052).
As shown in Table 5, six variables were associated with
death during hospitalization in univariate analysis, but seven
variables reached criteria to be included in the multivariate
model (p < 0.20). From these, only increasing age, hospitaliza-
tion at the ICU, and a primary site of infection other than UTI
proved to be independently associated to all-cause hospital
mortality.
Finally, to be older than 50 years (HR: 1.63; 95% CI:
1.18–2.27; p = 0.003) and presence of Enterobacteriaceae resistant
to third generation cephalosporins (HR: 2.31; 95% CI: 1.59–3.34;
p < 0.001) were independently associated with longer length of
stay.
Discussion
In this study, we  demonstrated that the presence of Entero-
bacteriaceae resistant to third generation cephalosporins was
quite common (26%) in cultures obtained in the ﬁrst 48 h of
hospitalization of adult patients admitted to a university hos-
pital in Brazil. The presence of invasive prosthesis or tunneled
catheters, previous use of cephalosporins, hospitalization in
the last six months, and be male proved to be risk factors inde-
pendently associated with the presence of these bacteria. Also,
the presence of resistant enterobacteria was associated with
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Table 2 – Univariate analysis of risk factors for patients with isolation of Enterobacteriaceae resistant to third-generation
cephalosporins in the ﬁrst 48 h of hospitalization.
Risk factor Cases
n = 62
Controls
n = 124
p-value OR (95% CI)
Patient transferred from another hospital, n (%) 10 (16.4) 14 (11.3) 0.331 1.54 (0.64–3.70)
Invasive prosthesis or tunneled catheters, n (%) 24 (44.4) 21 (17.4) <0.001 3.81 (1.87–7.78)
Stoma 11 (19.0) 6 (4.8) 0.002 4.60 (1.61–13.16)
Recurrence of UTI 18 (35.3) 27 (22.7) 0.088 1.86 (0.91–3.81)
Previous contact with health care services
Invasive procedures 24  (40.7) 20 (16.3) <0.001 3.53  (1.74–7.16)
Prior hospitalization in the last 6 months 33  (60.0) 24 (20.3) <0.001 5.88  (2.91–11.85)
Prior hospitalization in ICU in the last 6 months 12  (22.6) 11 (9.3) 0.018 2.85 (1.17–6.96)
Previous use of antimicrobials
Last 90 days
All 39 (73.6) 56 (47.1) 0.001 3.13 (1.54–6.37)
Cephalosporins 15 (28.3) 14 (11.8) 0.007 2.96 (1.31–6.710)
Quinolones 11 (21.2) 17 (14.3) 0.264 1.61 (0.69–3.73)
-lactam/-lactamase inhibitor 8 (15.1) 10 (8.4) 0.186 1.94 (0.72–5.23)
Last 12 months 38 (76.0) 41 (43.6) <0.001 4.09 (1.90–8.81)
Table 3 – Independent risk factors for the isolation of Enterobacteriaceae resistant to third generation cephalosporins in
samples collected in the ﬁrst 48 h of hospitalization.
Variable Coefﬁcient (ˇ) OR (95% CI) p-value
Male 0.980 2.66 (1.17–6.06) 0.019
Previous use of cephalosporins in last 90 days 1.333 3.79 (1.29–11.08) 0.015
Presence of invasive prosthesis or tunneled catheters 1.022 2.77 (1.10–6.97) 0.029
Hospitalization in the last 6 months 1.675 5.33 (2.29–12.44) <0.001
Table 4 – Clinical impact of the presence of Enterobacteriaceae resistant to third generation cephalosporins in samples
collected within the ﬁrst 48 h of hospitalization.a
Clinical endpoints Cases Controls p-value
Inappropriate empirical antibiotic therapy (%) 73.3 10.3 <0.001
Clinical response 0.029
Complete or partial resolution 30 (62.5) 87 (79.1)
Therapeutic failure or uncertain result 18 (37.5) 23 (20.9)
Length of stay, days, median (25–75) 13 (4.75–31.0) 5 (1.25–9.75) <0.001
Hospitalization in UCI 26  (44.1) 28 (22.6) 0.003
Hospital discharge condition (death), n (%) 13 (21.0) 13 (10.5) 0.052
a Analyses restricted to the subgroup of infected patients (46 cases and 108 controls).
Table 5 – Factors associated with death during hospitalization.
Variable Deceased Survivors p-value
Univariate
OR (95% CI) p-value
Multivariate
Age, years, average (SD) 62.1 (17.8) 48.7 (20.0) 0.002 1.03 (1.00–1.05) <0.001
Presence of 2 or more
comorbidities (%)
60.0  36.9 0.041 NS NS
Infection site other than
UTI
82.2 56.0 0.007 3.20 (1.12–9.26) 0.030
Immunosuppression 36.0 25.6 0.284 NS NS
Admission to ICU 72.0 18.8 <0.001 8.53 (3.08–23.66) <0.001
Inappropriate empirical
antibiotic therapy (%)
48.0  25.2 0.022 NS NS
Enterobacteriaceae resistant
to third generation
cephalosporins (cases) (%)
48.0  26.4 0.030 NS NS
Enterobacteriaceae other
than E. coli
56.0  24.9 0.059 NS NS
NS, non-signiﬁcant.
i s . 2 0
r
public-health concern. Infection. 2008;8:159–66.
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inadequate empirical antibiotic therapy and longer hospital
stay.
In recent years, the frequency of Enterobacteriaceae resistant
to third generation cephalosporins has increased and dissem-
inated in the hospital environment4,13–15 and more  recently
in non-hospital settings.5,6,16,17 In Brazil, most studies con-
ducted up to now determined the frequency and risk factors
associated with these pathogens in patients with nosocomial
infections.18,19 The frequency of Enterobacteriaceae resistant to
third generation cephalosporins in samples obtained during
the ﬁrst 48 h of hospitalization found in this study was con-
siderably high. The rate found in this study is in line with
other reports of nosocomial infection rates in small Brazil-
ian hospitals.20,21 In the few studies conducted in the country
with outpatients the ESBL production rates were consider-
ably lower.22,23 However, in the present study most cases had
had recent hospitalizations (68.4%) or were transferred from
other hospitals (16.4%), so they could not be considered as
community-acquired. Rather, it seems more  appropriate to
consider them as health care associated infections.
Notwithstanding the country of interest, most studies have
pointed to previous exposure to health care settings as risk
factor for the presence of ESBL-determined resistance among
Enterobacteriaceae identiﬁed in cultures obtained at the time of
hospital admission.7,24,25 Similarly, this study identiﬁed pre-
vious hospitalization in the last six months, and presence
of invasive prosthesis or tunneled catheters, and previous
use of cephalosporins as factors independently associated
with the presence of these bacteria. As for the predom-
inance of male patients, other studies also demonstrated
an increased frequency of ESBL-producing Enterobacteria-
ceae among men,9,24,26,27 but nonetheless this issue remains
controversial.8,28,29 According to Behar30 the discrepancies are
related to methodological differences between the studies,
especially the selection of the control group, as well as dif-
ferences in infection presentation and antibiotics prescribing
patterns between genders (e.g., women have UTI more  often).
In this study, the presence of resistant Enterobacteriaceae
was associated with poor clinical outcomes, such as longer
length of hospital stay, more  frequent hospitalizations at
the ICU, and worse clinical response to antibiotic therapy.
However, this ﬁnding should be interpreted with caution
since patients with resistant enterobacteria had higher mean
age and more  comorbidities. Inadequate antibiotic therapy
proved to be signiﬁcantly more  common among cases (73.3%
vs. 10.3%), and is one of the possible explanations for less
favorable outcomes observed among patients with resistant
enterobacteria. Delay to administer appropriate antibiotic
therapy correlated with a worse prognosis in several clini-
cal conditions.26,31,32 Finally, regarding hospital stay, previous
reports have shown longer length of stay of patients with
infections caused by resistant Gram-negative bacilli (GNB)
when compared to infections caused by sensitive GNB.33
This study has several limitations. First, it is a single
center study, involving a relatively small sample size (186
subjects), which might not be representative of the overall
patient population admitted to other hospitals in Brazil or
elsewhere. Thus, our ﬁndings must be validated in other
cohorts, both inside and outside Brazil. The characteristics
of the patients studied here prevent us from stating that 1 5;1  9(3):239–245
the resistant enterobacteria isolated in our patients were
community-acquired, being more  accurate to consider them
as associated with health care facilities. Finally, we  evalu-
ated ESBL producers and strains overexpressing AmpC as a
single group of enterobacteria resistant to third-generation
cephalosporins. The small number of isolates prevented us
from performing an analysis separating these two subgroups.
In conclusion, in the present study, consisting of adult
patients admitted to a university hospital of high complexity
in Brazil, the occurrence of enterobacteria resistant to third-
generation cephalosporins is quite common. The recognition
of risk factors associated with the presence of these bacte-
ria may have an impact on the choice of empirical antibiotic
therapy, particularly in patients with organ dysfunction.
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